MAP3K5 and infection: Further studies are now needed to confirm that GS-444217 and other promising ASK1 inhibitors do not impair antibiotic efficacy against common infections, such as Group B streptococcus, E. coli, Staphylococcus aureus, or Enterobacteriaceae infection.